Business Context and Reporting Period
This Form 8-K is a current report filed by Onconova Therapeutics, Inc. (note: metadata listed "Traws Pharma" but the filing text identifies "Onconova Therapeutics, Inc.") on September 29, 2015. The report covers events occurring in late September 2015, specifically regarding a material definitive agreement, preliminary financial condition for the quarter ended September 30, 2015, and a notice of delisting from the NASDAQ Global Select Market.
Key Financial Metrics
- Cash and Cash Equivalents: Management estimates approximately $22.2 million as of September 30, 2015. This is a preliminary, unaudited figure.
- Capital Raised: During the three months ended September 30, 2015, the Company sold 1,940,103 shares under its Sales Agreement with Cantor Fitzgerald & Co., generating net proceeds of $4,749,000.
- Revenue and Profit: The filing does not provide specific revenue, profit, or margin figures for the period, as the Company is still finalizing its third-quarter financial results.
- Debt and Liquidity: No specific debt figures are provided. Liquidity is indicated by the estimated cash balance of $22.2 million.
Material Changes and Events
- Sales Agreement Amendment: On September 30, 2015, the Company entered into Amendment No. 1 to its Sales Agreement with Cantor Fitzgerald & Co. This amendment extends the agreement, which was set to expire on October 8, 2015, until terminated by either party.
- NASDAQ Delisting Notice: The Company received notice from NASDAQ that its Market Value of Listed Securities (MVLS) had closed below the $50,000,000 minimum requirement for the NASDAQ Global Select Market for 30 consecutive business days.
Outlook, Risks, and Contingencies
- Compliance Period: The Company has a 180-day grace period (until March 28, 2016) to regain compliance with the MVLS requirement. Compliance is achieved if the MVLS closes at or above $50,000,000 for 10 consecutive business days.
- Delisting Risk: If compliance is not met by the deadline, the stock may be delisted. The Company is considering options, including transferring the listing to the NASDAQ Capital Market, which has lower requirements.
- Financial Reporting: The Company expects to announce finalized financial results for the third quarter of 2015 in November 2015. The current cash estimate is unaudited and subject to change.
- Forward-Looking Statements: The filing includes standard disclaimers regarding risks and uncertainties that could cause actual results to differ from expectations.
Investor Verification Checklist
- Verify the finalized cash balance and full financial results when announced in November 2015.
- Monitor the Company's Market Value of Listed Securities (MVLS) to ensure it meets the $50,000,000 threshold for 10 consecutive days before March 28, 2016.
- Review the full text of Amendment No. 1 to the Sales Agreement (Exhibit 10.1) for specific terms regarding future share sales.
- Confirm whether the Company files a plan to transfer listing to the NASDAQ Capital Market if Global Select compliance is not met.